| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2005 | WO2004100987A3 Methods of using il-1 antagonists to treat neointimal hyperplasia |
| 05/26/2005 | WO2004091538B1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 05/26/2005 | WO2004082619A3 Forms of 5-azacytidine |
| 05/26/2005 | WO2004073617A3 Tertiary amine functional complex polyester polymers |
| 05/26/2005 | WO2004073604A3 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity |
| 05/26/2005 | WO2004070008A3 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors |
| 05/26/2005 | WO2004062604A3 Treatment of cancer with 2-deoxyglucose |
| 05/26/2005 | WO2004048542A3 Mapks as modifiers of the rac, axin, and beta-catenin pathways and methods of use |
| 05/26/2005 | WO2004047719A3 Use of iminosugar derivatives to inhibit ion channel activity |
| 05/26/2005 | WO2004039321A8 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
| 05/26/2005 | WO2004037971A3 Use of heterocyclic amine-type compounds as neuroprotective agents |
| 05/26/2005 | WO2003084529A3 Low-pressure mercury vapor discharge lamp |
| 05/26/2005 | WO2003055475A8 Controlled release pharmaceutical formulation containing venlafaxine |
| 05/26/2005 | WO2003054145A3 Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment |
| 05/26/2005 | WO2003004039A9 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| 05/26/2005 | US20050113903 Medical device for delivering biologically active material |
| 05/26/2005 | US20050113773 irradiating a paste mixture of chitin and/or chitosan derivatives, to form hydrogels having antimicrobial activity, used in disposable diapers or as humectants in cosmetics |
| 05/26/2005 | US20050113595 C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 05/26/2005 | US20050113585 novel intermediates useful in the synthesis of 14 beta -hydroxy-1,14-carbonate-deacetylbaccatin III derivatives; 7,10-bistrichloroacetyl-10-deacetylbaccatin III; 13-dehydro-14 beta -hydroxy-7-triethylsilylbaccatin III; 13-dehydro-14 beta -hydroxy-7,10-bistrichloroacetyl-baccatin III 1,14-carbonate |
| 05/26/2005 | US20050113579 Antitumor agents; formed by refluxing mixture of amonafide with acetic acid |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113566 Inhibitors of C-FMS kinase |
| 05/26/2005 | US20050113554 Hyperbranched polymers |
| 05/26/2005 | US20050113529 Contain polyester side-arms which contain sulphone groups and are linked to polymer main chain via ester groups, which side-arms have been at least partially neutralized by sodium and lithium counterions; hair setting composition |
| 05/26/2005 | US20050113460 Compositions and methods relating to novel compounds and targets thereof |
| 05/26/2005 | US20050113459 Compositions for diabetes |
| 05/26/2005 | US20050113458 Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies |
| 05/26/2005 | US20050113457 Treatment of neuropathic pain or fibromyalgia |
| 05/26/2005 | US20050113456 Method of decreasing fat deposits and body weight in mammals and birds |
| 05/26/2005 | US20050113455 Method and composition for amelioration of pain |
| 05/26/2005 | US20050113454 Anti-viral compounds |
| 05/26/2005 | US20050113452 Composition and dosage form for sustained effect of levodopa |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113450 method of sterilization, sanitation, antisepsis, and disinfection, includes applying antimicrobial compounds to a surface; e.g. 2-[(3-{[4-chloro(methyl)anilino]sulfonyl}benzoyl)amino]-5-(trifluoromethyl)benzoic acid |
| 05/26/2005 | US20050113449 Hydrophobic carriers may increase the rate in which omega-3 fatty acids provide an effect, e.g., by administration by parenteral routes or by protection from degradation or increase of absorption in the gastrointestinal tract |
| 05/26/2005 | US20050113448 Via absorbent products (tampons, sanitary napkins) comprising thiolactomycin; toxic shock syndrome toxin-1 (TSST-1) |
| 05/26/2005 | US20050113447 Selective retinoid agonists |
| 05/26/2005 | US20050113446 Method of purifying pravastatin |
| 05/26/2005 | US20050113445 Administering a haloenol lactone as an anandamide amidohydrolase inhibitor; prefered is E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl) -2H-pyrane-2-one |
| 05/26/2005 | US20050113443 Modulation of airway inflammation in patients with cystic fibrosis and related diseases |
| 05/26/2005 | US20050113441 Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
| 05/26/2005 | US20050113440 Compounds that modulate PPAR activity and methods for their preparation |
| 05/26/2005 | US20050113438 Indolecarboxylic acid derivatives as plasminogen activator inhibitor inhibitors; anticoagulant, antiischemic, and anticarcinogenic agents; noninsulin-dependent diabetes, polycystic ovarian syndrome, cardiovascular disorders, atherosclerosis, alzheimer*s disease, chronic obstructive pulmonary disease |
| 05/26/2005 | US20050113437 Preparation of 3-azabicyclo [3.1.0] hexane derivatives |
| 05/26/2005 | US20050113435 Histamine-3 receptor ligands for diabetic conditions |
| 05/26/2005 | US20050113434 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury |
| 05/26/2005 | US20050113433 Diagnosing a subject in need of hemorrhagic or ischemic stroke treatment; administering 2-(N-anilino-)phenylacetic acid; |
| 05/26/2005 | US20050113432 Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer |
| 05/26/2005 | US20050113431 Method of treating isolated systolic hypertension |
| 05/26/2005 | US20050113430 2-[o-(aminoalkoxy)phenyl])-3-acylbenzothiazolines, e.g., 3-Acetyl-6-chloro-2-[2-(3-(N-(2-hydroxyethyl)-N-isopropylamino)-propoxy)-5-methoxyphenyl]benzothiazoline; treating pruritus or pain, particularly that caused by a rheumatic disease |
| 05/26/2005 | US20050113427 Use of peroxynirite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence |
| 05/26/2005 | US20050113426 Polyhydroxylated benzene-containing compounds |
| 05/26/2005 | US20050113424 E.g., 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperazinyl]propoxy}benzamidine; an antifungal agent with good pharmacokinetics and excellent antifungal action; side effect reduction such as nephrotoxicity; action to Mycomycetes |
| 05/26/2005 | US20050113422 5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-2,3-dihydro-indol-1-yl}-acetic acid methyl ester or an oxazole analogous compound; side effect reduction; non-insulin dependent diabetes; hypoglycemic agents; obesity; hyperlipemia; anticholesterol agents; atherosclerosis |
| 05/26/2005 | US20050113421 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders |
| 05/26/2005 | US20050113418 Improving the inhibition of gastric acid secretion in the treatment of a gastrointestinal disorder by the oral administration of a an acid labile H+, K+-ATPase inhibitor by administering two or more consecutive oral unit dose with 0.5-4 hour intervals; antisecretory, antiulcer agents, e.g., omeprazole |
| 05/26/2005 | US20050113417 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113415 Promoting the activity of glucocerebrosidease by administering a reversible competitive inhibitor such as iminosugars, e.g. calysegnines, isofagomines,N-alkyl-deoxynojirimycins; lysosomal storage disorders |
| 05/26/2005 | US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens |
| 05/26/2005 | US20050113413 Salt of 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]- N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine (THRX 326151); storage stable; nonhygroscopic; free-flowing amorphous powder; dosage form; muscarinic receptor antagonist; overactive bladder; incontinence |
| 05/26/2005 | US20050113412 Quinoline compounds and their uses |
| 05/26/2005 | US20050113411 Amino-substituted ethylamino beta2 adrenergic receptor agonists |
| 05/26/2005 | US20050113410 Crystalline alkali metal salt of zafirlukast such as potassium zafirlukast; stability in water; bioavailability; treating asthma |
| 05/26/2005 | US20050113409 Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith |
| 05/26/2005 | US20050113407 for example, (Naphthalen-2-yl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, (Naphthalen-1-yl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone |
| 05/26/2005 | US20050113406 Blood platelet aggregation inhibiting and antithrombotic effect; uniform crystal form; reproducable industrial scale manufacture |
| 05/26/2005 | US20050113405 Methods of treating rheumatoid arthritis using NF-kB inhibitors |
| 05/26/2005 | US20050113404 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates |
| 05/26/2005 | US20050113403 Method of treating mantle cell lymphoma |
| 05/26/2005 | US20050113402 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 05/26/2005 | US20050113401 Use of e.g. N-[(1R,S)-1-Cyclopropylethyl]-Normorphine for treating opiate, cocaine, or alcohol addiction |
| 05/26/2005 | US20050113400 Novel benzophenone derivatives or salts thereof |
| 05/26/2005 | US20050113399 Platelet ADP receptor inhibitors; ADP (adenosine 5'-diphosphate); thrombosis; contain thien-2-yl-sulfonylurea groups; 1-(thiophen-2-ylsulfonyl)-3-(4-(7-fluoro-6-(sec or tert-amino)-1-oxo-(3,4-dihydro)isoquinolin-2(1H)-yl)aryl)urea |
| 05/26/2005 | US20050113398 Use of 5-halo or trifluoromethylpyrimidine-2,4-diamine compounds to treat proliferative diseases such as tumorgenic cancers |
| 05/26/2005 | US20050113397 Broad spectrum antifungal agent; 1,6-beta-glucan synthetase inhibitors; pyrido(1,2-a)benzimidazole derivatives or benzo(4,5)imidazo(1,2-a)pyridine derivatives |
| 05/26/2005 | US20050113395 with pyrrolo[2,3-d]pyrimidine compounds e.g. Methyl-[4-methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; Janus Kinase 3 inhibitors |
| 05/26/2005 | US20050113394 Abacavir or salts thereof and a highly compressible carrier such as microcrystalline cellulose; dosage forms; treating HIV; high drug loading tablets of acceptable size for patient compliance |
| 05/26/2005 | US20050113392 6,7-dihydro-5H-pyrazolo(1,2-a)pyrazol-1-ones |
| 05/26/2005 | US20050113391 Anti-hypertensive composition and methods of treatment |
| 05/26/2005 | US20050113387 Pyrazine derivatives and pharmaceutical use thereof |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113385 Method of treatment |
| 05/26/2005 | US20050113384 Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents |
| 05/26/2005 | US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 05/26/2005 | US20050113382 Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists |
| 05/26/2005 | US20050113381 Pyridazinone aldose reductase inhibitors |
| 05/26/2005 | US20050113380 [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists |
| 05/26/2005 | US20050113379 Corticotropin releasing factor (CRF); affective disorders, anxiety disorders, stress-related disorders, eating disorders and substance abuse; eg 5-(1-Ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine |
| 05/26/2005 | US20050113378 As inhibitors of the retinoic acid-metabolism, as drugs; breast cancer; psoriasis |
| 05/26/2005 | US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors |
| 05/26/2005 | US20050113376 ethanol and celecoxib, deracoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib, meloxicam or parecoxib |
| 05/26/2005 | US20050113374 Benzodioxepine derivatives |
| 05/26/2005 | US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample |
| 05/26/2005 | US20050113372 Therapy for ischemic-repefusion injuries; liver disorders; antiarrhythmia agents; anticancer agents; astaxanthin |
| 05/26/2005 | US20050113371 Antifungal agent for topical use |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113369 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113367 Mixture of angiotensin II receptor antagonist and diuretics (a thiazide); hypotensive agents; low toxicity |